Research article
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
-
* Corresponding authors: Jos Jonkers j.jonkers@nki.nl - Maarten van Lohuizen m.v.lohuizen@nki.nl - Alexandra M Pietersen gmsamp@nus.edu.sg
- † Equal contributors
1 Molecular Genetics and Cancer Genomics Centre, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
2 Institute of Physiological Chemistry, The Medical Faculty Carl-Gustav Carus, Fetscherstraß 74, 01307 Dresden, Germany
3 Division of Molecular Biology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
4 Department of Experimental Therapy, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
5 Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
6 Molecular Pharmacology, Genome Institute of Singapore, 60 Biopolis Street, 138672 Singapore
7 National Cancer Centre Singapore/Duke-NUS GMS, 11 Hospital Drive, 169610 Singapore
8 Current address: Biomedical Analysis Center, Tsinghua University, Beijing 100084, PR China
Breast Cancer Research 2009, 11:R63 doi:10.1186/bcr2354
See related editorial by Wicha, http://breast-cancer-research.com/content/11/5/108
Published: 26 August 2009Additional files
Additional file 1:
A PDF file containing a figure that shows that DZNep prevents sphere-formation in three independent BRCA1-deficient cell lines. Phase contrast images are shown of KB1P-3.12, 30.3 and 40.1 cells three days after plating in serum-free medium with defined growth factors on ultra-low binding plates in the presence of 5 μM 3-deazaneplanocin A (DZNep) or dimethyl sulfoxide (DMSO).
Format: PDF Size: 1.8MB Download file
This file can be viewed with: Adobe Acrobat Reader
